Adnexus

Adnexus is a private, pre-revenue biotech company pioneering an AI-driven approach to monoclonal antibody discovery against infectious diseases. Its core technology, the Sutra™ platform, analyzes viral targets to identify immutable epitopes and facilitates rapid antibody generation from human B-cells of recovered patients. The company has demonstrated proof-of-concept by identifying conserved targets for HIV, SARS-CoV-2, and Monkeypox, positioning itself in the high-need market for broad-spectrum antiviral therapeutics.

Sutra™ AI platform for identifying conserved, immutable viral epitopes and a proprietary method for generating fully human monoclonal antibodies from convalescent patient B-cells.

Adnexus competes in the crowded field of AI-driven drug discovery, facing off against well-capitalized players like Absci, Recursion, and Schrödinger, as well as large biopharma internal efforts. Its specific focus on convalescent B-cells for antibody generation is a differentiating, but unproven, approach in a market valuing clinical validation.